EGFR and neoplasm: Oncogenic-driven tumors for which a TKI was routinely available as the initial treatment included EGFR, ALK, and ROS1. These tumors have been characterized as weakly immunogenetic by frequently having no or low tumor PD-L1 expression, low tumor mutational burden, and low numbers of tumor-infiltrating lymphocytes cultivating in an immunosuppressive tumor microenvironment.30